Reproductive Endocrinology — MCQs

Reproductive Endocrinology Indian Medical PG Practice Questions and MCQs

Question 161: Precocious puberty is most characteristic of which of the following conditions?

A. Jaffe's Syndrome
B. Monostotic fibrous dysplasia
C. Albright's syndrome (Correct Answer)
D. Osteogenesis imperfecta

Explanation: **Explanation:** **Albright’s Syndrome** (specifically McCune-Albright Syndrome) is the correct answer because it is a classic cause of **GnRH-independent (peripheral) precocious puberty**. It is characterized by a clinical triad: 1. **Polyostotic fibrous dysplasia:** Multiple cystic bone lesions. 2. **Café-au-lait spots:** Large, irregular skin pigmentations (often described as having "Coast of Maine" borders). 3. **Autonomous endocrine hyperfunction:** Most commonly presenting as precocious puberty due to estrogen secretion from ovarian cysts. The underlying pathophysiology involves a somatic mutation in the **GNAS gene**, leading to constitutive activation of the G-protein signaling (adenylate cyclase), which mimics the effect of continuous hormonal stimulation (FSH/LH) on the ovaries. **Analysis of Incorrect Options:** * **Jaffe’s Syndrome:** This is a variant of fibrous dysplasia that presents with café-au-lait spots and bone lesions but **lacks** the endocrine abnormalities (precocious puberty) seen in McCune-Albright. * **Monostotic fibrous dysplasia:** This involves a single bone lesion and is not associated with systemic endocrine manifestations or skin pigmentation. * **Osteogenesis imperfecta:** A genetic disorder of Type 1 collagen characterized by brittle bones, blue sclera, and hearing loss, but it does not cause precocious puberty. **High-Yield Clinical Pearls for NEET-PG:** * **McCune-Albright Syndrome** is more common in girls. * It is a **peripheral** cause of precocious puberty; therefore, LH/FSH levels will be suppressed (low), and the patient will not respond to GnRH analogues. * The café-au-lait spots in this syndrome are typically unilateral and do not cross the midline. * **Treatment:** Aromatase inhibitors (e.g., Letrozole) or Estrogen receptor antagonists (e.g., Tamoxifen) are used to manage the precocity.

Question 162: Which of the following prostaglandins induces aromatase activity in endometrial stromal cells?

A. PGE1
B. PGF2
C. PGE2 (Correct Answer)
D. PGD2

Explanation: **Explanation:** The correct answer is **PGE2**. This question tests the understanding of the molecular pathophysiology of endometriosis and estrogen-dependent endometrial growth. **Why PGE2 is correct:** In conditions like endometriosis, there is a high concentration of **Prostaglandin E2 (PGE2)**. PGE2 acts as a potent stimulator of the enzyme **aromatase** (encoded by the CYP19A1 gene) in endometrial stromal cells. Aromatase converts androgens (androstenedione and testosterone) into estrogens (estrone and estradiol). This creates a **positive feedback loop**: PGE2 increases aromatase → aromatase increases local estrogen production → estrogen further stimulates COX-2 expression → COX-2 produces more PGE2. This cycle drives the proliferation and survival of ectopic endometrial tissue. **Analysis of Incorrect Options:** * **PGE1:** A synthetic analogue (Misoprostol) is used for cervical ripening and medical abortion, but it is not the primary endogenous inducer of aromatase in the endometrium. * **PGF2α:** This prostaglandin is primarily responsible for **myometrial contractions** during labor and menstruation. It causes vasoconstriction of the spiral arteries, leading to endometrial ischemia and shedding, rather than inducing aromatase. * **PGD2:** This is the major prostaglandin produced in the brain and by mast cells; it is involved in sleep regulation and allergic responses, with no significant role in endometrial aromatase induction. **High-Yield Clinical Pearls for NEET-PG:** * **Normal vs. Ectopic Endometrium:** Aromatase is virtually **absent** in normal, healthy endometrium but is **highly expressed** in endometriosis, adenomyosis, and uterine fibroids. * **COX-2 Inhibitors:** Because PGE2 drives this cycle, NSAIDs (COX-2 inhibitors) are used in endometriosis management to reduce both pain and local estrogen production. * **Aromatase Inhibitors (e.g., Letrozole):** These are sometimes used off-label for refractory endometriosis to break the estrogen-PGE2 feedback loop.

Question 163: A sample of cervical mucus is taken on Day 12 of the menstrual cycle. The mucus is thin, clear, and elastic. When placed under a microscope, what microscopic finding would be expected?

A. Clear field devoid of bacteria
B. Thick mucus with background bacteria
C. A fern pattern characteristic of estrogen (Correct Answer)
D. Clearly defined, parabasal cells

Explanation: **Explanation:** The correct answer is **C. A fern pattern characteristic of estrogen.** **1. Why the correct answer is right:** On Day 12 of a typical 28-day menstrual cycle (the late follicular/pre-ovulatory phase), estrogen levels are at their peak. High estrogen levels act on the cervical glands to produce mucus that is thin, watery, alkaline, and rich in sodium chloride. When this mucus is dried on a glass slide, the crystallization of the salts creates a characteristic microscopic appearance known as **arborization** or a **"fern pattern."** This change increases the "Spinnbarkeit" (elasticity), facilitating sperm penetration and survival. **2. Why the incorrect options are wrong:** * **Option A:** While the mucus is clear clinically, a "clear field" under a microscope is not a diagnostic finding for cycle dating. The presence or absence of bacteria is not the defining feature of the periovulatory phase. * **Option B:** Thick mucus with background cellularity/bacteria is characteristic of the **luteal phase** (post-ovulation). Under the influence of **progesterone**, cervical mucus becomes thick, viscous, and cellular, which inhibits the fern pattern (anti-estrogenic effect). * **Option D:** Parabasal cells are a feature of vaginal cytology in low-estrogen states (e.g., menopause or prepuberty), not a finding in cervical mucus during the reproductive cycle. **3. NEET-PG High-Yield Pearls:** * **Ferning (Arborization):** Indicates high estrogen; disappears after Day 21 due to progesterone. * **Spinnbarkeit Test:** Measures the elasticity of mucus. Maximum elasticity (>10 cm) occurs just before ovulation. * **Progesterone Effect:** Causes "Beading" or a cellular pattern; it is the basis for using cervical mucus as a natural contraceptive method (Billings method). * **Palm Leaf Pattern:** Another name for the fern pattern seen in cervical mucus.

Question 164: Which of the following clinical features is seen in Polycystic Ovarian Disease (PCOD)?

A. Hirsutism
B. Secondary amenorrhea
C. Streak ovaries (Correct Answer)
D. Elevated FSH/LH ratio

Explanation: **Explanation:** The question asks for a clinical feature **not** typically associated with Polycystic Ovarian Disease (PCOD/PCOS), as **Streak Ovaries** is the characteristic finding in **Turner Syndrome (45,XO)** and Pure Gonadal Dysgenesis, not PCOD. **1. Why "Streak Ovaries" is the Correct Answer (The Exception):** In PCOD, the ovaries are typically **enlarged** (volume >10cc) with multiple small peripheral follicles (string-of-pearls appearance). In contrast, **streak ovaries** occur due to accelerated atresia of germ cells, resulting in fibrous tissue bands devoid of follicles. This is a hallmark of hypergonadotropic hypogonadism (e.g., Turner Syndrome). **2. Analysis of Incorrect Options:** * **Hirsutism:** This is a classic feature of PCOD, resulting from **hyperandrogenism**. It is clinically graded using the Modified Ferriman-Gallwey score. * **Secondary Amenorrhea:** PCOD is the most common cause of chronic anovulation. Patients typically present with oligomenorrhea or secondary amenorrhea due to the lack of progesterone withdrawal. * **Elevated FSH/LH ratio:** This is a distractor. In PCOD, the **LH/FSH ratio is increased** (typically >2:1 or 3:1) because of increased GnRH pulse frequency. Therefore, a "decreased" FSH/LH ratio is seen, but the presence of hormonal imbalance remains a core feature. **High-Yield Clinical Pearls for NEET-PG:** * **Rotterdam Criteria (2 out of 3):** 1. Clinical/Biochemical Hyperandrogenism, 2. Oligo/Anovulation, 3. Polycystic ovaries on USG. * **Gold Standard Investigation:** Transvaginal Ultrasound (TVS). * **Metabolic Link:** Hyperinsulinemia and Insulin Resistance are central to the pathogenesis. * **Drug of Choice:** Clomiphene Citrate (traditional) or **Letrozole** (current first-line for ovulation induction).

Question 165: Which of the following is NOT a typical sign of hyperandrogenism seen in Polycystic Ovary Syndrome (PCOS)?

A. Hirsutism
B. Clitoromegaly (Correct Answer)
C. Androgenic Alopecia
D. Acne

Explanation: **Explanation:** In Polycystic Ovary Syndrome (PCOS), hyperandrogenism is typically **biochemical** (elevated serum testosterone/androstenedione) or **clinical** (signs of mild-to-moderate androgen excess). **Why Clitoromegaly is the correct answer:** Clitoromegaly is a sign of **virilization**, not simple hyperandrogenism. Virilization involves extreme androgen excess that causes masculine physical changes, including clitoromegaly (clitoral index >35 $mm^2$), deepening of the voice, and increased muscle mass. If a patient presents with these signs, clinicians must rule out more serious pathologies like **Androgen-Secreting Ovarian Tumors** (e.g., Sertoli-Leydig cell tumors) or **Adrenal Tumors**, as PCOS rarely produces androgen levels high enough to cause structural changes like clitoromegaly. **Analysis of Incorrect Options:** * **A. Hirsutism:** The most common clinical sign of PCOS (seen in ~70% of cases), characterized by terminal hair growth in a male-pattern distribution (measured by the Modified Ferriman-Gallwey score). * **C. Androgenic Alopecia:** Thinning of scalp hair, typically in the vertex or crown area, is a recognized cutaneous manifestation of hyperandrogenism in PCOS. * **D. Acne:** Persistent inflammatory acne, especially in the "U-zone" (jawline), is a common dermatological marker of elevated circulating androgens. **NEET-PG High-Yield Pearls:** * **Rotterdam Criteria (2003):** Diagnosis requires 2 out of 3: (1) Oligo/Anovulation, (2) Hyperandrogenism (Clinical/Biochemical), (3) Polycystic ovaries on USG. * **Virilization vs. Hyperandrogenism:** PCOS = Hyperandrogenism; Ovarian/Adrenal Tumors = Virilization. * **Gold Standard for Hirsutism:** Modified Ferriman-Gallwey (mFG) score; a score $\geq$ 8 is significant in the Indian population.

Question 166: A 28-year-old lady is suspected to have polycystic ovarian disease. Samples for testing LH and FSH are best taken on which days of the menstrual cycle?

A. Day 4
B. Day 10 (Correct Answer)
C. Days 13-15
D. Days 24-26

Explanation: **Explanation:** In the context of Polycystic Ovarian Syndrome (PCOS), the hormonal hallmark is an **elevated LH:FSH ratio** (typically >2:1 or 3:1). While baseline hormonal testing in a normal cycle is usually done on Day 2 or 3, PCOS is characterized by chronic anovulation and a "steady state" of hormonal imbalance. **Why Day 10 is the correct answer:** In a typical 28-day cycle, Day 10 falls in the **late follicular phase**. In patients with PCOS, the characteristic elevation of LH is most pronounced and consistently demonstrable during this period. Testing at this stage highlights the failure of the follicular transition and the persistent high levels of LH that contribute to the-hyperandrogenism and follicular arrest seen in this condition. **Analysis of Incorrect Options:** * **Day 4 (Early Follicular Phase):** While often used for baseline FSH to check ovarian reserve, it may not show the peak diagnostic LH elevation characteristic of PCOS as clearly as the mid-to-late follicular phase. * **Days 13-15 (Periovulatory Phase):** This is the time of the physiological LH surge in normal cycles. Testing here would make it impossible to distinguish between a normal mid-cycle surge and the pathological LH elevation of PCOS. * **Days 24-26 (Luteal Phase):** During this phase, progesterone is dominant. In PCOS, patients are often anovulatory, meaning there is no true luteal phase, making testing during these days unreliable for diagnosis. **High-Yield Clinical Pearls for NEET-PG:** * **LH:FSH Ratio:** A ratio >2:1 is suggestive, though no longer a mandatory Rotterdam criterion for diagnosis. * **Rotterdam Criteria:** Diagnosis requires 2 out of 3: (1) Clinical/biochemical hyperandrogenism, (2) Oligo/anovulation, (3) Polycystic ovaries on USG. * **Gold Standard for PCOS Morphology:** Transvaginal Ultrasound (TVS) showing ≥12 follicles (2-9mm) or ovarian volume >10ml. * **Best Initial Test for Hirsutism in PCOS:** Free testosterone levels.

Question 167: What is the investigation of choice for hyperprolactinemia?

A. TRH estimation
B. LH estimation
C. Prolactin estimation (Correct Answer)
D. Estradiol estimation

Explanation: **Explanation:** **Why Prolactin estimation is the correct answer:** Hyperprolactinemia is defined as a persistent elevation of serum prolactin levels (>25 ng/mL in non-pregnant females). The **investigation of choice** to diagnose this condition is the direct measurement of **Serum Prolactin levels**. Ideally, the sample should be taken in a fasting state, in the morning, and without recent breast stimulation or pelvic examination, as these can cause physiological spikes. If a single value is mildly elevated, the test should be repeated to confirm the diagnosis before initiating imaging or treatment. **Why the other options are incorrect:** * **TRH estimation (A):** While primary hypothyroidism causes an increase in TRH (which stimulates prolactin release), TRH levels are not routinely measured clinically. Instead, TSH is measured to rule out hypothyroidism as a secondary cause. * **LH estimation (B):** LH levels are often suppressed in hyperprolactinemia (leading to anovulation), but they are not diagnostic of the condition itself. * **Estradiol estimation (D):** Hyperprolactinemia leads to a hypoestrogenic state, but measuring estradiol is non-specific and does not identify the underlying cause. **High-Yield Clinical Pearls for NEET-PG:** * **Hook Effect:** In cases of giant prolactinomas with extremely high prolactin, a lab artifact may show falsely low levels. Serial dilution of the serum is required for an accurate reading. * **Gold Standard Imaging:** Once hyperprolactinemia is confirmed biochemically, **Contrast-enhanced MRI of the Sella** is the investigation of choice to rule out a pituitary adenoma. * **Drug of Choice:** **Cabergoline** (a dopamine agonist) is the first-line treatment, preferred over Bromocriptine due to better efficacy and fewer side effects. * **Rule out:** Always exclude pregnancy (hCG test) and hypothyroidism (TSH test) in any patient presenting with elevated prolactin.

Question 168: Which of the following is a definition of delayed puberty in a female?

A. No breast budding by 13 years of age
B. Menarche after 16 years of age (Correct Answer)
C. Menarche more than 1 year after the onset of breast budding
D. FSH less than 20 mIU/mL in a 16-year-old female

Explanation: ### Explanation Delayed puberty in females is clinically defined by the absence of secondary sexual characteristics or the failure of progression to menarche within a specific timeframe. **Why Option B is Correct:** In clinical practice, delayed puberty is diagnosed if: 1. There is **no breast development (Thelarche) by age 13**. 2. There is a gap of more than **5 years** between thelarche and menarche. 3. **Menarche has not occurred by age 16**, regardless of the presence of secondary sexual characteristics. Therefore, menarche after 16 years of age fits the classic diagnostic criteria for delayed puberty (specifically, primary amenorrhea with secondary sexual characteristics). **Analysis of Incorrect Options:** * **Option A:** While "No breast budding by 13 years" is *also* a definition of delayed puberty, Option B is often prioritized in MCQ contexts regarding the upper limit for menarche. (Note: In many standard textbooks, both A and B are valid; however, B specifically addresses the timing of the final stage of puberty). * **Option C:** The normal interval between thelarche and menarche is typically 2–3 years. A 1-year interval is normal, not delayed. Delay is defined as >5 years. * **Option D:** FSH levels are used to *classify* the cause (Hypergonadotropic vs. Hypogonadotropic) but are not part of the *definition* of delayed puberty itself. **High-Yield Clinical Pearls for NEET-PG:** * **Sequence of Puberty:** Thelarche (Breast) → Adrenarche/Pubarche (Hair) → Growth Spurt → Menarche (Mnemonic: **T**en **A**pes **G**o **M**ad). * **First Sign:** Thelarche is usually the first visible sign (Growth spurt is the first physiological change). * **Most Common Cause:** Constitutional Delay of Growth and Puberty (CDGP) is common, but **Turner Syndrome (45,XO)** is the most common pathological cause of primary amenorrhea/delayed puberty. * **Kallmann Syndrome:** Characterized by hypogonadotropic hypogonadism and anosmia.

Question 169: What is the commonest cause of female pseudohermaphroditism?

A. Virilizing ovarian tumor
B. Ovarian dysgenesis
C. Exogenous androgen
D. Congenital adrenal hyperplasia (Correct Answer)

Explanation: **Explanation:** **Female pseudohermaphroditism** (now referred to as 46,XX Disorder of Sexual Development) is characterized by a normal female genotype (46,XX) and normal ovaries, but with ambiguous or virilized external genitalia due to excess androgen exposure in utero. **Why Congenital Adrenal Hyperplasia (CAH) is correct:** CAH is the **most common cause** of female pseudohermaphroditism, accounting for approximately 90-95% of cases. It is an autosomal recessive disorder, most commonly due to **21-hydroxylase deficiency**. This enzyme defect impairs cortisol synthesis, leading to an increase in Adrenocorticotropic Hormone (ACTH). Elevated ACTH overstimulates the adrenal cortex, diverting precursors into the androgen pathway, resulting in fetal virilization. **Analysis of Incorrect Options:** * **A & C (Virilizing ovarian tumor / Exogenous androgen):** While maternal exposure to androgenic drugs or maternal androgen-secreting tumors (like Luteoma of pregnancy) can cause virilization of a female fetus, these are significantly rarer than CAH. * **B (Ovarian dysgenesis):** This (e.g., Turner Syndrome) typically presents with streak gonads and primary amenorrhea, but the external genitalia are usually normally developed female, not virilized. **NEET-PG High-Yield Pearls:** * **Most common enzyme deficiency in CAH:** 21-hydroxylase (leads to high 17-OH Progesterone). * **Prader Staging:** Used to grade the degree of virilization of external genitalia. * **Clinical Presentation:** Look for salt-wasting (hyponatremia, hyperkalemia) in the classic form. * **Internal Genitalia:** In female pseudohermaphroditism, the **Mullerian structures (uterus, tubes, upper vagina) are always present** because there is no Anti-Mullerian Hormone (AMH).

Question 170: What is a primary use of GnRH analogues?

A. Galactogenesis
B. Polycystic Ovarian Syndrome (PCOS) (Correct Answer)
C. Contraception
D. None of the above

Explanation: **Explanation:** **GnRH analogues** (such as Leuprolide or Goserelin) are synthetic peptides modeled after the natural Gonadotropin-Releasing Hormone. Their primary mechanism involves initial stimulation followed by **downregulation and desensitization** of the pituitary GnRH receptors, leading to a state of "medical oophorectomy" or hypogonadotropic hypogonadism. **Why PCOS is the correct answer:** In PCOS, there is a characteristic derangement of the HPO axis, often featuring high-frequency GnRH pulses and an elevated LH:FSH ratio. GnRH analogues are used in PCOS primarily to **suppress ovarian androgen production** and to prevent premature LH surges during controlled ovarian hyperstimulation (COH) for In-Vitro Fertilization (IVF). By suppressing the endogenous LH, these analogues help manage hirsutism (refractory cases) and improve follicular synchronization during infertility treatments. **Why other options are incorrect:** * **Galactogenesis:** This is the process of milk production, primarily regulated by **Prolactin**. GnRH analogues actually suppress the estrogen levels required for ductal development and do not promote lactation. * **Contraception:** While GnRH analogues inhibit ovulation, they are **not** used as primary contraceptives due to their side effect profile (bone mineral density loss, vasomotor symptoms) and the requirement for parenteral administration. Combined Oral Contraceptive Pills (COCPs) remain the gold standard. **NEET-PG High-Yield Pearls:** * **Flare Effect:** Initial administration of GnRH agonists causes a transient rise in LH/FSH before downregulation occurs (usually after 7–10 days). * **GnRH Antagonists:** (e.g., Cetrorelix) provide immediate suppression without the "flare effect." * **Other Uses:** Endometriosis, Uterine Fibroids (to reduce size pre-operatively), Central Precocious Puberty, and Prostate Cancer. * **Add-back Therapy:** When using GnRH analogues for >6 months, small doses of estrogen/progesterone are added to prevent osteoporosis and hot flashes.

Practice by Chapter

Hypothalamic-Pituitary-Ovarian Axis

Practice Questions

Disorders of Puberty

Practice Questions

Hirsutism and Virilization

Practice Questions

Primary Ovarian Insufficiency

Practice Questions

Hyperprolactinemia

Practice Questions

Hyperandrogenism

Practice Questions

Metabolic Dysfunction in PCOS

Practice Questions

Neuroendocrine Disorders and Reproduction

Practice Questions

Hormonal Evaluation and Testing

Practice Questions

Ovulation Induction

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free